SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
CELG Analysis & Videos »
CELG: Bull or Bear?
Celgene (CELG): Cancer progress boosts biotech
CELG
+4.82%
in
107 days
Filed under: Newsletters, Stock screen, Stocks to Buy  "Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay.In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review. "This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals. <>"However, despite the risks, there are times wh...
|
Celgene (CELG): Play offense and defense with biotech
CELG
+14.52%
in
58 days
(closed on 08/19/09)
Filed under: Newsletters, Stocks to Buy "Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt. In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential." "Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies. <>"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammator...
|
New Index of Cancer Diagnostic and Therapeutic Stocks
CELG
|
|
|
+0.00%
in
12 hours
(closed on 04/13/09)
By Mike Havrilla on 4/12/09 at BioMedReports.com The table at the link below includes statistics for the 40 companies in the ETF Innovators Emerging Cancer Diagnostic and Therapeutic Stock Index, which is featured at BioMedReports.com in the health indexes section of the site. The index will track the performance of stocks with market caps below $200M at the inception date of 4/12/09 from a starting value of 2,632. <> A World Health Organization report released last year es...
|
Nine for '09 Stock Picks Start Strong
CELG
|
|
|
-20.79%
in
94 days
(closed on 04/12/09)
<> 
The nine stock picks I posted in mid-December are off to a strong start in the new year, with seven of the stocks registering gains and a 14.5% gain for the group as an equal-weight average versus a 1.1% gain for the S&P 500 SPDR ETF (SPY). Click on any of the links below for my most recent articles on each company.
The four smallest, defensive healthcare stock picks are leading the group with an average gain of 30.6% thanks to an 87.3% gain for Javelin Pharma (JAV) and a 42.9% gain for Caraco Pharma (CPD) while...
|
My UpDown Virtual Investing Portfolio
CELG
|
|
|
-7.62%
in
7 days
(closed on 01/08/09)
<> 
Start earning real money with zero risk while improving your trading skills and strategies at the UpDown Virtual Investing website -- just click on the image above or any of the text links to the site in this article to sign up today. My stats and profile are featured in the accompanying table and on my blog site below the last posted entry. I started trading at the UpDown on 11/23/08 with a gain of 32.5% through today -- my profile name on the site is 'ETFinnovators' with a portfolio of long positions and link...
|
Small, Defensive '09 Stock Picks Are Soaring
CELG
|
|
|
+3.54%
in
13 days
(closed on 01/01/09)
<> 
The nine defensive stock picks I wrote about last week are off to a very strong start, posting a 7.4% gain as an equally-weighted average compared to a 1% gain for the S&P 500 SPDR ETF (SPY). The biggest gains came from the smallest companies in the index – Caraco Pharma (CPD) was up 40% while Javelin Pharma (JAV) increased by 19% in the past week and has more than doubled since I first wrote about it in early December .
Despite a drop in shares of Altria (MO) over the past week, I have added to ...
|
Nine for '09: Stock Picks for the New Year
CELG
|
|
|
+8.23%
in
7 days
(closed on 12/18/08)
<> Below are nine stock picks for 2009, which are taken from the 1,000 company database of ETF Innovators [ETFI] Indexes, and which I own in my personal brokerage account. Given my cautious stance toward the economy and stock market, the picks have a defensive theme favoring the healthcare sector as a source of defensive growth companies.
1.) Consumer Staples – Tobacco: Altria Group (MO) has lost about 30% of its market value since spinning off the international tobacco operations into a separate public company as Philip Morris< />< />< />< /><>< />< />< />< /><>< />< />< />< /><>< />< />< />< />< />< />< />< /><>...
|
Stock Ideas from ETF Innovators New Indexes
CELG
|
|
|
-10.18%
in
4 days
(closed on 12/11/08)
<> Below is a list of 14 stock opportunities from various ETF Innovators [ETFI] indexes, which includes a database of over 1,000 companies. The companies are chosen across a full spectrum of market cap and risk level from a variety of industry groups.
From the ETFI Highly Defensive PerformIdex , I believe Altria Group (MO) and Pfizer (PFE) are defensive dividend, value buys at current levels as each company currently pays a dividend of $1.28 per share annually – resulting in historically high dividend yields for bot<>< />< /><><><>< />< /><><><>< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><>< />< /><><><><>< />< />< />< />< />< />< />< />...
|
Celgene (CELG): Blockbuster potential?
CELG
-11.71%
in
206 days
(closed on 06/22/09)
Filed under: Newsletters, Stocks to Buy "The medical arena has long been my favorite sectors; perhaps the best opportunities within the medical sector will be with companies who provide life-saving products for the treatment of serious diseases," says Dave Dyer. In The Dave Dyer Newsletter, he explains, "That is why Celgene (NASDAQ: CELG) is an excellent choice in this economy." Here's his look at this "recession-resistant" company. <>"Celgene is a multinational biopharmaceutical company with a $29 billion market cap and no debt. Revlimid is their blockbuster drug with multi-billion dollar poten...
|
Stock Picks for Healthy Returns
CELG
|
|
|
+7.89%
in
12 days
(closed on 12/07/08)
<> Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X.
Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one.
...
|
ETFI Highly Defensive PerformIdex: Lower Volatility, Higher Returns
CELG
|
|
|
-17.93%
in
16 days
(closed on 11/25/08)
<> 
The accompanying table includes an updated version of the ETFI Highly Defensive PerformIdex of 40 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. The updates include removing retail exposure at CVS Caremark (CVS) and Tesco (TSCDY) in favor of keeping Wal-Mart (WMT) as the major beneficiary of a trade-down effect and mass merchant discounter, which integrates groceries, pharmacy, everyday clothing, c...
|
People Bullish on CELG
People Bearish on CELG
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on CELG |
More Resources
|
About Celgene Corp
- Answers.com
